# Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)

> clinical trial · VERIFIED · 2026-06-29

Status: RECRUITING · Sponsor: Feldan Therapeutics · Condition: Nodular Basal Cell Carcinoma

- Company: Feldan Therapeutics
- Sector: dermatology
- Primary source: https://clinicaltrials.gov/study/NCT07670858

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.